Localization of p21-activated Protein Kinase gamma -PAK/Pak2 in the Endoplasmic Reticulum Is Required for Induction of Cytostasis*

Zhongdong HuangDagger, Jun Ling, and Jolinda A. Traugh§

From the Department of Biochemistry, University of California, Riverside, California 92521

Received for publication, December 10, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The intracellular localization and physiological functions of the p21-activated protein kinase gamma -PAK have been examined in human embryonic kidney 293T and COS-7 cells. At 1-4 days post-transfection, cell division is inhibited by the expression of wild type (WT) gamma -PAK and the mutant S490A, whereas cells expressing S490D and the inactive mutants K278R and T402A grow exponentially, indicating a role for gamma -PAK in the induction of cytostasis. WT gamma -PAK and S490A are localized in a region surrounding the nucleus identified as the endoplasmic reticulum (ER), as determined by immunofluorescence, whereas K278R, T402A, and S490D lack localization. As shown by sucrose density gradient centrifugation, WT gamma -PAK, S490A, and endogenous gamma -PAK are distributed among the high density (ER-associated), intermediate density, and low density fractions, whereas the mutants that do not inhibit cell division are present only as soluble enzyme. The amount of endogenous gamma -PAK associated with the particulate fractions is increased 4-fold when cell division is inhibited by ionizing radiation. gamma -PAK in the ER and intermediate density fractions has high specific activity and is active, whereas the soluble form of gamma -PAK has low activity and is activable. The importance of localization of gamma -PAK is supported by data with the C-terminal mutants S490D and Delta 488; these mutants have high levels of protein kinase activity but do not induce cytostasis and are not bound to the ER. A model for the induction of cytostasis by gamma -PAK through targeting of gamma -PAK to the ER is presented in which gamma -PAK activity and Ser-490 are implicated in the regulation of cytostasis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p21-activated protein kinases include group I PAKs1 (alpha -PAK (Pak1), beta -PAK (Pak3), and gamma -PAK (Pak2) and group II PAKs (Pak 4, 5, and 6). The members of group I are activated by autophosphorylation through binding of the small G proteins Cdc42 and Rac1, whereas the activation of group II enzymes has not been clearly identified (1-5). Within the group I PAK family, gamma -PAK has distinct properties compared with other PAK isoforms. gamma -PAK appears to be ubiquitous, whereas alpha - and beta -PAK have greater tissue specificity. gamma -PAK is primarily inactive in dividing cells and is transiently activated when cells are subjected to moderate stress conditions such as hyperosmolarity, ionizing radiation, and DNA-damaging drugs (1, 6, 7). Phosphatidylinositol 3-kinase and tyrosine kinase activity have been identified as upstream activators of gamma -PAK in response to ionizing radiation and araC (7). A function for gamma -PAK was suggested initially by microinjection of active gamma -PAK into early frog embryos; active gamma -PAK inhibited cell cleavage, whereas inactive gamma -PAK had no inhibitory effect (8). gamma -PAK is also involved in apoptotic signal transduction and can be cleaved and activated in vitro by caspase 3, a member of the cysteine-aspartic acid protease cascade activated during apoptosis, and in vivo under anti-Fas apoptotic induction (9-11). Because of the cytotoxic nature of gamma -PAK, the enzyme activity and protein level are tightly regulated. In addition to transient activation by Cdc42 in response to moderate stress, gamma -PAK is degraded through the proteosome pathway after ubiquitination (12). Inactive gamma -PAK has been shown to be protected from degradation and to accumulate by association with other proteins, as shown with c-Abl (12).

In contrast, alpha -PAK responds to growth-related signals, such as platelet-derived growth factor (13), epidermal growth factor (14), inflammatory factors such as interleukin-1 and angiotensin (15) and to sphingosine (16). Subcellular localization has been shown to be important for the physiological functioning of alpha -PAK. alpha -PAK localizes to cortical actin structures in growth factor-stimulated cells (13), resulting in cytoskeletal reorganization, including membrane ruffling, filopodia extension, focal complex formation, and a decrease in actin stress fibers (17, 18). Interaction of alpha -PAK with the adaptor protein Nck leads to translocation of alpha -PAK to the cellular membrane and stimulation of activity (13, 19, 20).

All members of the group I PAKs contain two functional domains, an N-terminal regulatory domain (residues 1-246 in gamma -PAK) and a C-terminal catalytic domain (residues 247-524). The G protein binding site, which is also conserved in the Ste20 PAK isoform in Saccharomyces cerevisiae (21), is located at residues 73-108 in gamma -PAK (1). In gamma -PAK, Lys-278 coordinates ATP in the active site, and the mutant K278R is kinase inactive (9, 22). In the absence of an activator, gamma -PAK is autophosphorylated at five sites but not activated (23, 24). Upon binding of Cdc42(GTP) or cleavage by caspase 3, an additional three sites are autophosphorylated, resulting in activation of the protein kinase. A site shown to be involved in activation of gamma -PAK is Thr-402, the conserved threonine in the activation loop; the mutant T402A (mimicking nonphosphorylated threonine) has little protein kinase activity (9, 23). K/RRXS/T is the preferred recognition sequence phosphorylated by gamma -PAK (25). Ser-490 in the sequence KRGS is a potential autophosphorylation site for gamma -PAK and for phosphorylation by protein kinase C. Ser-490 is located adjacent to a region involved in binding to the beta -subunit of the trimeric G protein (26). This region is removed in the truncated mutant Delta 488 that lacks the C-terminal 36 amino acid residues.

Conditions of hyperosmolarity and the addition of sphingosine to cultured cells result in translocation of gamma -PAK to the particulate fraction and subsequent activation of the enzyme (6, 27). It was thus of interest to examine whether intracellular localization had an effect on the cytostatic activity of gamma -PAK. In this study, we examined the subcellular localization and cytostatic activity of gamma -PAK in mammalian cells as shown by sucrose density gradient centrifugation and immunocytochemistry. Recombinant WT gamma -PAK and S490A are associated primarily with the particulate fraction and are localized in the endoplasmic reticulum (ER). In contrast, the kinase-inactive gamma -PAK mutants K278R and T402A and the C-terminal mutants S490D and Delta 488 are present only as soluble enzymes and are present in the nucleus and the cytosol. WT gamma -PAK and S490A inhibit cell growth, whereas the other mutants have no inhibitory effect. Taken together, the data show that subcellular localization of active gamma -PAK is essential for the induction of cytostasis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- GTPgamma S was from Roche Molecular Biochemicals. [gamma -32P]ATP was purchased from PerkinElmer Life Sciences. Dulbecco's modified Eagle's medium and fetal bovine serum were from Invitrogen. BA85 nitrocellulose membranes were from Schleicher & Schuell. Amersham Biosciences was the source for glutathione-Sepharose 4 beads. Pfu polymerase was from Stratagene. Restriction enzymes were purchased from New England Biolabs. pcDNA3.1+ mammalian expression plasmid was from Invitrogen. Rabbit anti-calreticulin polyclonal antibody was from Affinity Bioreagents. Protein G-Sepharose, goat anti-gamma -PAK polyclonal antibody N19, and horseradish peroxidase-conjugated mouse anti-goat IgG were from Santa Cruz Biotechnology. Fluorescein isothiocyanate-conjugated goat anti-rabbit and tetramethylrhodamine isothiocyanate-conjugated goat anti-mouse secondary antibodies were from Sigma. Caspase 3 was expressed in Escherichia coli strain BL-21 and purified as described previously (9). The Geneclean kit was from BIO 101, Inc. Qiagen was the source for the Qiaprep spin kit, the plasmid maxi kit, and Superfect transfection reagent. The enhanced chemiluminescence kit was from Amersham Biosciences. Mouse anti-hemagglutinin antigen (HA) tag monoclonal antibody 12CA5 was generously provided by Dr. Xuan Liu, University of California, Riverside. The E. coli expression plasmid pET21(b) encoding the gene for caspase 3 (CPP 32) was generously provided by Drs. G. S. Litwack and E. S. Alnemri, Thomas Jefferson University, Philadelphia, PA.

Construction of Mammalian Expression Plasmids-- The cDNA for gamma -PAK from rabbit and the gamma -PAK mutants K278R, T402A, S490A, and S490D were prepared as described previously and subcloned into the pBlue-NK plasmid (9, 24). To make the C-terminal deletion mutant Delta 488, a 1.2-kb DNA fragment encoding residues 1-487 was generated by PCR with primers GATCCATATGTCTGATAACGGAGAAC and TCTAGAGGATCCTTATTTTTCCACATCCAT. The PCR product was cleaved with NdeI and XbaI and ligated into the pBlue-NK plasmid. To prepare the double mutants K278R/S490A and K278R/S490D, a 1.2-kb DNA fragment encoding residues 1-402 was cleaved from the pBlue-NK gamma -PAK K278R plasmid with NdeI and NcoI and inserted into pBlue-NK gamma -PAK S490A or S490D precleaved with NdeI and NcoI. The resulting double mutations were confirmed by DNA sequencing. The Kozak consensus sequence ACCATG followed by the DNA sequence encoding a HA tag, YPYDVPDYA, was inserted immediately before the start site of gamma -PAK using PCR and was verified by DNA sequencing. HA-tagged rabbit gamma -PAK was cloned into the pcDNA3.1+ expression plasmid at the KpnI and XbaI sites.

Transfection of Mammalian Cells-- The monkey kidney cell line COS-7 and the human embryonic kidney cell line 293T were maintained by serial passage in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 °C in a 5% CO2 incubator. Transient transfection of 293T and COS-7 cells was carried out with Superfect transfection reagent as described by the manufacturer. Approximately 5 × 105 cells were plated in 75-cm2 flasks; the following day, the cells were transfected for 3 h with 10 µg of pcDNA3.1+ HA-tagged WT or mutant gamma -PAK. Two µg of pcDNA3.1+ LacZ was cotransfected as a control of transfection efficiency. At 48 h post-transfection, the cells were harvested, washed with phosphate-buffered saline (PBS), resuspended in 100 µl of COWIE buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM dithiothreitol, 1% Nonidet P-40, and 0.5 mM phenylmethylsulfonyl fluoride) and frozen at -70 °C. The cells were thawed and vortexed, and the lysate was centrifuged at 16,000 × g for 5 min at 4 °C; the resulting supernatant and particulate fractions were used for further analysis.

Western Blotting and Assay for gamma -PAK Activity-- To detect HA-tagged gamma -PAK, the supernatant and particulate fractions from ~5 × 105 293T cells were analyzed by SDS-PAGE on 7.5% polyacrylamide gels and the protein transferred onto nitrocellulose membranes. The samples were probed with mouse anti-HA tag monoclonal antibody 12CA5 (1:1,000) followed by goat anti-mouse IgG conjugated with horseradish peroxidase (1:10,000) and detected by chemiluminescence.

To assay for protein kinase activity, gamma -PAK was immunoprecipitated from the Nonidet P-40-solubilized lysate by incubation with 2 µg of anti-HA monoclonal antibody 12CA5 for 2 h at 4 °C. After the addition of 20 µl of protein G-Sepharose, incubation was continued for 1 h. The beads were washed twice with radioimmune precipitation assay buffer and three times with PBS.

To activate gamma -PAK by cleavage with caspase 3, the immunoprecipitates were suspended in 30 µl of caspase cleavage buffer (25 mM HEPES, pH 7.5, 5 mM EDTA, 2 mM dithiothreitol, and 0.1% CHAPS) and incubated in the presence or absence of caspase 3 for 30 min at 37 °C. For activation of gamma -PAK by Cdc42(GTPgamma S), the immunoprecipitates were incubated in 30 µl of PBS with 1 µg of Cdc42 preloaded with 0.18 mM GTPgamma S for 5 min at 30 °C. Protein kinase activity was assayed in a volume of 70 µl in 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 30 mM 2-mercaptoethanol, 0.2 mM ATP, 1 µg of histone 4, and [gamma -32P]ATP (2,000 dpm/pmol) for 30 min at 30 °C; these were kinetically valid conditions. Phosphorylation of histone 4 was analyzed by SDS-PAGE on 15% polyacrylamide gels followed by autoradiography.

To analyze protein kinase with similar amounts of recombinant WT and mutant gamma -PAK protein, the number of cells was adjusted, and the level of protein was determined by Western blotting. Lysates were prepared from 2.4 × 107 cells for WT gamma -PAK and S490A, from 9 × 106 cells for Delta 488, and from 3 × 106 cells for K278R, S490D, and T402A and assayed as described above. Radiolabeled histone 4 was excised and counted in a scintillation counter. Aliquots (10 µl) of the same immunoprecipitates were analyzed by SDS-PAGE and immunoblotted with anti-HA antibody to ensure that identical amounts of proteins were used. To assay for protein kinase activity with the synthetic heptapeptide S3 (AKRESAA), 1 mM S3 was added to the assay described above in place of histone 4. Phosphorylated S3 was analyzed on P81 phosphocellulose paper, as described previously (25).

Immunolocalization of Expressed gamma -PAK and Analysis of Cell Proliferation-- Approximately 1 × 105 COS-7 cells were plated onto glass coverslips and transfected with 5 µg of pcDNA3.1+ HA-tagged gamma -PAK plasmid. At 48 h post-transfection, the cells were washed twice with PBS, fixed with 4% paraformaldehyde for 20 min, and washed three times with PBS. After blocking with 5% fetal bovine serum for 1 h, the cells were probed for gamma -PAK with mouse anti-HA antibody (1:200) and for the ER marker calreticulin with rabbit polyclonal antibody PA3-900 (1:200). The cells were washed three times with PBS, then incubated with goat anti-mouse IgG conjugated with rhodamine (1:200) to identify the HA tag, and goat anti-rabbit IgG conjugated with fluorescin (1:200) to identify calreticulin. After washing twice with PBS, the coverslips were mounted on glass slides and analyzed using a confocal laser scanning imaging system. The images were analyzed with Bio-Rad Confocal AssistantTM image analysis program. The transfection efficiency was monitored by cotransfection of gamma -PAK with the pcDNA3.1+ LacZ plasmid, and LacZ was assayed 2 days post-transfection. The transfection efficiency was ~7% for COS-7 cells.

To examine the effects of expression of WT and mutant gamma -PAK on cell proliferation, COS-7 cells were transfected on coverslips, probed with anti-HA antibody, and stained as described above. The cells were monitored every 24 h for 4 days using a fluorescent microscope. About 100-600 cells were counted at each time point from 10 images for each sample; the 5 images nearest the average were used for quantitative measurements.

293T cells were grown on collagen-coated six-well plates and transfected with HA-tagged WT gamma -PAK and the mutants K278R, T402A, S490A, S490D, and Delta 488 in the pTracer vector (Invitrogen) using Superfect reagent. The pTracer vector also contained the enhanced green fluorescent protein reporter gene under a different promoter, which allowed coexpression of gamma -PAK and green fluorescent protein in the same cell. One and 2 days post-transfection, living cells were examined for the green fluorescent protein positive signal under an inverted microscope (Eclipse TE300, Nikon). The same sample was fixed with 4% formaldehyde for in situ immunofluorescence staining of gamma -PAK with anti-HA antibody as described. The coexpression of gamma -PAK and green fluorescent protein was evaluated using a fluorescence microscope (Eclipse E800, Nikon). Total cells (1,000-2,000) and fluorescent cells were counted from multiple images.

Sucrose Density Gradient Fractionation-- To correlate the subcellular localization with gamma -PAK activity, sucrose density gradient fractionation of the postnuclear supernatant from 293T cells was carried out as described (28, 29) with some modifications. At 48 h post-transfection, ~3 × 106 cells were harvested and washed with PBS and with buffer A as described by Sfeir and Veis (29). The cell pellet was resuspended and kept on ice for 5 min in 250 µl of buffer A and then homogenized with a Dounce homogenizer (pestle B). The homogenization was monitored under a light microscope and generally resulted in >98% cell lysis. After centrifugation at 1,000 × g for 10 min at 4 °C, the pellet was discarded, and the postnuclear supernatant was fractionated as described below.

Preparation of sucrose density gradients followed the procedure described by Rexach and Schekman (28) with some modifications. The postnuclear supernatant (250 µl) was loaded onto the top of a 2.5-ml gradient and centrifuged for 2 h at 30,000 rpm in a Beckman rotor (SW 60Ti) at 4 °C. Eleven fractions of 250 µl each were collected from the bottom of the tube. The protein in each fraction was precipitated by the addition of an equal volume of 10% trichloroacetic acid and 50% acetone at -20 °C for 1 h. After centrifugation at 16,000 × g for 5 min at 4 °C, the pellet was washed twice with cold acetone, air-dried, resuspended in 30 µl of SDS sample buffer, and analyzed by SDS-PAGE on 7.5% polyacrylamide gels. The proteins were blotted onto a nitrocellulose membrane and probed with antibody to the HA tag. Endogenous gamma -PAK was detected with goat anti-gamma -PAK polyclonal antibody N19 followed by horseradish peroxidase-mouse anti-goat IgG.

Calreticulin was detected with rabbit antibody PA3-900 followed by horseradish peroxidase-goat anti-rabbit IgG antibody. Ionizing radiation of 293T cells was performed as described previously (6). Cells were then incubated for 2 h before analysis of localization of gamma -PAK.

To examine gamma -PAK activity, Nonidet P-40 was added at a final concentration of 1% to a 30-µl sample from each fraction from the sucrose density gradient. The samples were incubated in the presence and absence of caspase 3 for 30 min at 37 °C and assayed with histone 4 as described above. Phosphorylation of H4 was quantified using a Bio-Rad phosphorimaging IMAGEQuant program. Specific activity was determined by assaying for protein kinase activity under kinetically valid conditions (see above), and gamma -PAK protein was quantified by immunoblotting. The cleavage of gamma -PAK by caspase 3 was confirmed by immunoblotting with anti-HA antibody after SDS-PAGE, as described above, to detect HA-tagged gamma -PAK p58 (full-length) and p27 (caspase-cleaved N terminus) in the fractions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of gamma -PAK Expression on Cell Proliferation-- To examine the effects of gamma -PAK expression on cell proliferation, recombinant WT gamma -PAK and three mutants were expressed in COS-7 cells and analyzed over a 4-day period. Expression of gamma -PAK was detected by immunofluorescence using anti-HA tag antibody, and antibody to calreticulin was used to determine the total number of cells. Approximately 7% of the cells were transfected, and the number of cells increased ~6-fold over the 4-day period, with a doubling time of 24 h (Fig. 1A). The number of cells expressing WT gamma -PAK remained constant over time, whereas the nontransfected cells continued dividing. The approximate number of cells expressing K278R on day 1 was comparable with the WT gamma -PAK; however, the cells with K278R continued dividing over the first 3 days and remained at that level on day 4, the time limit for protein expression through transient transfection. S490A had an expression pattern similar to that of WT gamma -PAK, whereas expression of S490D was comparable with that of K278R. The results indicate that expression of WT gamma -PAK and S490A resulted in induction of cytostasis, whereas K278R and S490D had no effect on cell division.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Cytostatic effect of gamma -PAK expressed in COS-7 and 293T cells. A, COS-7 cells were plated on coverslips and then transfected with pcDNA3.1+ HA-tagged WT or mutant gamma -PAK. The cells were fixed and probed with anti-HA tag antibody and anti-calreticulin antibody at the times indicated. The numbers of cells expressing recombinant WT or mutant gamma -PAK were counted using a laser confocal fluorescent microscope. The numbers were determined from five representative images. B, 293T cells were transfected and processed as described in A. The numbers of cells expressing recombinant WT or mutant gamma -PAK were counted using a laser confocal fluorescent microscope. The numbers were determined from counting more than 500 cells from representative images.

Experiments with 293T cells showed that the number of cells expressing the WT gamma -PAK and S490A remained constant over a 2-day incubation period, whereas the nontransfected cells continued dividing. Thus, the percentage of cells expressing these two forms of gamma -PAK was reduced from 21-24% on day 1 to 10-11% on day 2 (Fig. 1B). Cells expressing the kinase-inactive mutants K278R and T402A and the C-terminal mutants S490D and Delta 488 were expressed at around 30% on days 1 and 2, indicating that 293T cells tranfected with these mutants continued dividing. Thus, the data supported the conclusions reached with COS-7 cells, that WT gamma -PAK and S490A induced a cytostatic response.

Analysis of Expressed Recombinant gamma -PAK-- The WT and mutant forms of HA-tagged gamma -PAK were analyzed after expression in 293T cells. gamma -PAK in the supernatant and particulate fractions was analyzed by SDS-PAGE and immunoblotting with antibody to the HA tag. As shown in Fig. 2A, WT gamma -PAK was present in both the supernatant and the particulate fractions. The amount of recombinant WT gamma -PAK in the particulate fraction was 80% of that in the supernatant. Recombinant gamma -PAK comigrated on SDS-PAGE with the major band of endogenous gamma -PAK (58 kDa) present in the soluble and particulate fractions (as detected with N19 antibody).


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 2.   Differential expression and protein kinase activity of gamma -PAK in 293T cells. Approximately 5 × 106 293T cells, transfected with HA-tagged WT or mutant forms of gamma -PAK, were harvested after 48 h and lysed in 100 µl of radioimmune precipitation assay buffer in the presence of 1% Nonidet P-40 and separated into supernatant and particulate fractions by centrifugation at 16,000 rpm. A, 20 µg of each cell lysate was analyzed by SDS-PAGE, and expression of gamma -PAK was detected by Western blotting with antibody to the HA tag. Endogenous gamma -PAK in nontransfected cells was detected with antibody N19 to gamma -PAK. p58 and p60 identify the two forms of gamma -PAK. The relative amounts of gamma -PAK protein are indicated, as quantified by the NIH Image processing program; recombinant WT gamma -PAK in the supernatant and endogenous gamma -PAK in the supernatant are separately standardized to 1. B, 20 µg of each cell lysate was immunoprecipitated with anti-HA antibody, preincubated in the presence or absence of caspase 3, and assayed for protein kinase activity with histone 4. The samples were analyzed by SDS-PAGE followed by autoradiography. Autoradiograms of phosphorylated H4 are shown. Phosphorylation of H4 was quantified by counting the excised H4 band in a scintillation counter. Phosphorylation of H4 by WT gamma -PAK in the absence of caspase 3 was set at 1.

The kinase-inactive mutant K278R was expressed at a level 8.8-fold higher than the recombinant WT enzyme but was present only in the supernatant (Fig. 2A). A similar expression pattern was observed with T402A, which contained a mutated autophosphorylation site in the activation loop. When two mutants of the potential autophosphorylation site Ser-490 were examined, S490A (mimicking nonphosphorylated serine) was expressed at a level slightly less than WT gamma -PAK and was present in both fractions. The level of S490D (mimicking phosphoserine) was 8.1-fold higher than the WT gamma -PAK, a level similar to that of the kinase-inactive mutants, and was present only in the supernatant. The kinase-active mutant Delta 488, which lacked the C-terminal 36 amino acid residues including Ser-490, was expressed at a 3.3-fold higher level than the WT and was present only in the supernatant. With the double mutants K278R/S490A and K278R/S490D, the amount of expressed protein and the pattern of expression were similar to those of K278R. Wild type gamma -PAK and S490A migrated as a 58-kDa protein on SDS-PAGE, whereas K278R, T402A, S490D, and the double mutants migrated at 60 kDa. In contrast, the catalytic domain of gamma -PAK was expressed at levels 20-50-fold lower than those of the full-length wild-type protein and was highly unstable in 293T cells as well as in insect cells (data not shown). The level of expression of WT gamma -PAK was ~40% of the endogenous gamma -PAK protein in 293T cells. The relative levels of expression and mobility on SDS-PAGE of WT gamma -PAK and the mutants are the same in COS-7 and 293T cells.

Protein Kinase Activity of Wild Type and Mutant gamma -PAK Expressed in 293T Cells-- To measure the protein kinase activity of gamma -PAK expressed in 293T cells, ~5 × 106 cells were collected at 48 h post-transfection. gamma -PAK was immunoprecipitated from the cell lysates with anti-HA antibody and assayed with the specific substrate histone 4. Basal gamma -PAK activity was observed with WT gamma -PAK, S490A, S490D, and Delta 488, which was enhanced further upon cleavage with caspase 3 (Fig. 2B). The immunoprecipitate of S490D had higher kinase activity, consistent with the higher protein expression level of this mutant. K278R, and T402A had essentially no protein kinase activity either before or after cleavage, as expected.

To measure the relative specific activity of the different forms of gamma -PAK, the number of 293T cells was adjusted to obtain approximately the same amount of gamma -PAK; the cells were collected at 48 h post-transfection, and gamma -PAK was immunoprecipitated and assayed with histone 4 and peptide S3. As shown by the immunoblot in Fig. 3A (bottom panel), approximately the same amount of gamma -PAK protein was present in each sample. In the absence of an activator, similar low levels of basal gamma -PAK activity were observed with WT gamma -PAK, S490A, and Delta 488, with very low activity for S490D. Cleavage with caspase 3 or binding of Cdc42(GTPgamma S) stimulated phosphorylation of H4 to a similar extent. This was 2-3-fold when assayed with histone 4 or with S3 (Fig. 3, B and C), whereas the activity of S490D was increased 6-fold because of a lower basal activity.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Activity of recombinant gamma -PAK expressed in 293T cells. The cell lysate was prepared as described in Fig. 2. gamma -PAK was immunoprecipitated from the supernatant fraction with anti-HA tag antibody to give equal amounts of gamma -PAK protein for each mutant. The immunoprecipitates were preincubated in the presence and absence of caspase 3 or Cdc42(GTPgamma S) and assayed for protein kinase activity with histone 4. The samples were analyzed by SDS-PAGE followed by autoradiography. A, autoradiograms of phosphorylation of H4 by gamma -PAK are as indicated. A Western blot of the immunoprecipitates used for this assay is shown in the bottom panel of A. B, phosphorylation of H4 was quantified by excision of the H4 band and counted in a scintillation counter. Phosphorylation of H4 by WT gamma -PAK in the absence of an activator was set at 1. C, assays were carried out with S3 as substrate after preincubation in the presence or absence of caspase 3. Phosphorylation of H4 and S3 by nonactivated WT gamma -PAK was set at 1.

Immunolocalization of Recombinant Wild Type and Mutant gamma -PAK-- To examine the subcellular localization of gamma -PAK, COS-7 cells transfected with WT and mutant forms of gamma -PAK were probed with anti-HA tag antibody; fluorescence was visualized by confocal microscopy. WT gamma -PAK was localized around the nucleus in a broad band, as shown in Fig. 4. In contrast, K278R was present both in the cytosol and in the nucleus. S490A was localized around nucleus in a pattern similar to that of WT gamma -PAK, whereas S490D lacked distinct localization, similar to that observed with K278R. To identify the site of localization of WT gamma -PAK and S490A around the nucleus, the cells were probed with antibody against the ER marker calreticulin. As shown by image overlays (yellow), WT gamma -PAK and S490A colocalized specifically with calreticulin in the ER. When 293T cells transfected with WT gamma -PAK were examined in a similar manner, identical results were obtained. In addition, T402A and Delta 488 were present in both the cytosol and the nucleus (data not shown), similar to that observed with K278R and S490D (Fig. 4).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Localization of gamma -PAK in COS-7 cells by immunofluorescence. COS-7 cells were plated on coverslips, transfected with pcDNA3.1+ HA-tagged WT or mutant gamma -PAK. At 48 h post-transfection, the cells were washed, fixed, and probed with anti-HA tag antibody and anti-calreticulin antibody. Recombinant HA-tagged gamma -PAK was visualized with mouse anti-HA tag monoclonal antibody 12CA5 and TRITC-conjugated goat anti-mouse IgG. The ER was visualized with rabbit anti-ER marker calreticulin antibody and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG.

Subcellular Localization of Endogenous and Recombinant gamma -PAK by Sucrose Density Gradient Centrifugation-- To examine the subcellular localization of gamma -PAK further, the postnuclear supernatant from 293T cells was subjected to sucrose density gradient centrifugation. After centrifugation, endogenous gamma -PAK was identified in nontransfected cells by Western blotting with anti-gamma -PAK antibody, and recombinant gamma -PAK was identified by anti-HA antibody. Fractions 1-10 contained a gradient ranging from 55 to 15% sucrose, respectively, whereas fraction 11 was the position of the sample loading. As shown in Fig. 5A, endogenous gamma -PAK in actively dividing cells was localized in three places in the gradient, in fractions 1-4 (high density; particulate), in fractions 6 and 7 (intermediate density; particulate), and in fractions 10 and 11 (low density; soluble). The ER marker calreticulin, identified with anti-calreticulin antibody, was colocalized with gamma -PAK in the ER (fractions 1-4) and was present in soluble fractions 10 and 11. 


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Distribution of the gamma -PAK protein and protein kinase activity to the ER as determined by sucrose density gradient centrifugation. The postnuclear supernatant was prepared from transfected and nontransfected 293T cells incubated for 48 h and subjected to sucrose density gradient fractionation. A, endogenous gamma -PAK was detected with anti-gamma -PAK antibody N19. Recombinant gamma -PAK was detected with anti-HA tag antibody. The ER was identified with anti-calreticulin antibody. B, irradiated 293T cells were treated with ionizing radiation, incubated for 2 h, and the lysates were subjected to sucrose density gradient centrifugation as in A. gamma -PAK was detected with anti-gamma -PAK antibody. 293T cells transfected with the mutant K278R were used as a control. The amount of gamma -PAK in different sucrose density fractions was quantified with the NIH Image program. C, the sucrose density gradient fractions (200 µl each fraction) were pooled as 1-4 (ER-associated fractions), 5-8 (intermediate density fractions), and 9-11 (soluble fractions). HA-tagged WT gamma -PAK was immunoprecipitated from the pooled fractions, incubated in the presence or absence of caspase 3, and assayed with histone 4. The 32P incorporated into histone 4 was analyzed by SDS-PAGE followed by phosphorimaging quantification.

Expressed WT gamma -PAK (Fig. 5A) was distributed among fractions 1-4 (ER), fractions 6 and 7 (intermediate density), and fractions 10 and 11 (soluble). S490A, which also inhibited growth, was present in fractions 1-4 and fractions 10 and 11 with a small amount of protein at the intermediate density. In contrast, the inactive forms of gamma -PAK, K278R, T402A, and double mutants K278R/S490A and K278R/S490D were present only at the top of the gradient in fractions 9-11. Interestingly, the kinase-active mutant S490D was also present only in fractions 9-11. These results correlated well with the immunocytochemistry data showing that native and recombinant WT gamma -PAK, as well as S490A, were localized on the ER.

It is important to note that in dividing cells, the ER-associated and intermediate density fractions contained 10 and 5% of the total endogenous gamma -PAK protein, respectively; the majority of the endogenous gamma -PAK was present as the soluble form. In comparison, the majority of the recombinant WT gamma -PAK and S490A were located in the particulate fractions. To examine this further, 293T cells were subjected to ionizing radiation to inhibit cell proliferation. Under these conditions, more than half of the endogenous gamma -PAK was translocated to the ER (36%) and intermediate density fractions (20%) (Fig. 5B). The mutant K278R was not translocated to the ER after ionizing radiation.

Because S490D had the same intracellular distribution profile as the inactive mutants of gamma -PAK, but also had high protein kinase activity, the role of the C-terminal region in subcellular localization was examined further using the truncated mutant Delta 488. Like S490D, Delta 488 was detected only as a soluble form (Fig. 5A). These data indicated that the C-terminal region was required for localization of gamma -PAK in the ER. A comparison of the data with S490A and S490D suggested that phosphorylation at Ser-490 could have a role in regulating the release of gamma -PAK from the ER. The results with the double mutations K278R/S490A and K278R/S490D indicated that localization of S490A in the ER could be overruled by the K278R mutation.

To examine gamma -PAK activity in the different subcellular fractions, HA-tagged WT gamma -PAK was immunoprecipitated from pooled fractions 1-4, 5-8, and 9-11. The immunoprecipitates were preincubated in the absence or presence of caspase 3 and assayed for protein kinase activity with histone 4. The specific activity was calculated based on the phosphorylation of histone 4 and the amount of gamma -PAK protein in the fractions. The ER-associated form of gamma -PAK (fractions 1-4) and gamma -PAK with the intermediate density fraction (fractions 5-8) were active and were not activated further by cleavage with caspase 3 (Fig. 5C). In contrast, the soluble form of gamma -PAK was activated 3-fold by caspase 3.

A comparison of endogenous gamma -PAK with that of the recombinant WT was measured in a similar manner. As shown in Fig. 6A, gamma -PAK activity in nontransfected cells was also associated with the ER (fractions 1-4) and in the intermediate density fractions (fractions 5-8). gamma -PAK activity associated with the ER could not be activated further upon cleavage by caspase 3. The soluble form (fractions 9-11) had the lowest activity and could be activated further by cleavage with caspase 3 (Fig. 6A). Upon expression of recombinant WT gamma -PAK, total gamma -PAK activity was increased ~35% and was distributed in a pattern similar to the endogenous enzyme. gamma -PAK in the ER-associated and intermediate fractions was not activated by caspase 3, whereas the soluble form was activated by such cleavage. gamma -PAK was cleaved by caspase 3 to an equivalent extent in all three fractions, as shown in the immunoblots by the appearance of the p27 fragment containing the N-terminal region of gamma -PAK (Fig. 6B). This cleavage was dependent on prior dissociation of gamma -PAK from the ribosome. When gamma -PAK was associated with the ER, the protein was protected from cleavage (data not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Comparison of endogenous and recombinant gamma -PAK activity. The sucrose density gradient fractions were carried out as described in Fig. 5. Thirty µl of each fraction was incubated in the presence or absence of caspase 3 and assayed with histone 4; phosphorylation was analyzed by SDS-PAGE and quantified by phosphorimaging. A, activity of gamma -PAK in each sucrose density fraction. B, the sucrose density gradient fractions were pooled as 1-4 (ER-associated fractions), 5-8 (intermediate density fractions), and 9-11 (soluble fractions). The activity of the recombinant WT was calculated by subtraction of the endogenous gamma -PAK activity in nontransfected cells from the total activity in transfected cells. gamma -PAK protein was determined by Western blotting as shown in Fig. 5, and the specific activity was calculated using these values. Cleavage of recombinant gamma -PAK is shown after immunoprecipitation and analysis by SDS-PAGE and Western blotting.

The specific activity of gamma -PAK was calculated from the activity measurements of endogenous gamma -PAK with H4 and the protein content in the sucrose density gradient. The particulate forms of gamma -PAK had significantly higher specific activities (20-fold and 27-fold, respectively) than the soluble form (Fig. 6B). Cells transfected with recombinant gamma -PAK had ceased dividing, which correlated with significantly higher levels of gamma -PAK associated with the particulate fractions; 50% of the gamma -PAK protein was associated with the ER, and 15% was present in the intermediate density fractions. The ER-associated and intermediate forms of recombinant WT gamma -PAK had 5- and 10-fold higher specific activities compared with the soluble form. The results indicated that endogenous and recombinant gamma -PAK in ER and intermediate density fractions were highly active and that the level of gamma -PAK associated with particulate fractions was significantly greater when cell growth was inhibited.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The effects of gamma -PAK on cell proliferation were examined by the expression of WT and mutant gamma -PAK in COS-7 and 293T cells. The number of cells expressing WT gamma -PAK and S490A remained constant over a 4-day period, indicating that both WT and S490A inhibit cell growth. With the kinase-inactive and -activable C-terminal mutants S490D and Delta 488, the cell number increased exponentially along with the nontransfected cells, indicating that these mutants have no inhibitory effect on cell growth. The inhibitory effect of WT gamma -PAK expressed in COS-7 and 293T cells was also observed with NIH 3T3 cells and with cells infected with retroviral expression of gamma -PAK (data not shown). The data indicate that expression of the WT gamma -PAK or S490A induces cytostasis.

Recombinant WT gamma -PAK and S490A are associated with the ER as shown by immunocytochemistry and by sucrose density gradient centrifugation; the protein kinases are also detected in the intermediate density fractions and as soluble enzymes. In contrast, the active mutants S490D and Delta 488, and the inactive mutants K278R and T402A, are present in both the nucleus and the cytosol and do not bind tightly to the ER, as determined by sucrose density gradient centrifugation. The ER and intermediate density fractions with WT or S490A contain >50% of the total recombinant gamma -PAK protein. These particulate forms of gamma -PAK are already active and cannot be activated further, whereas soluble gamma -PAK has a low specific activity and can be activated by cleavage with caspase 3. This pattern is the same as that of native gamma -PAK in dividing cells, except that only 15% of the endogenous gamma -PAK is associated with the ER and intermediate density fractions. Considering that proliferating cells have primarily inactive endogenous gamma -PAK, ionizing radiation was used to render 293T cells in the quiescent state. Within 2 h after ionizing radiation, ~50% of endogenous gamma -PAK was translocated to the ER. The major difference between cells transfected with WT gamma -PAK or S490A, and cells transfected with kinase-inactive mutants K278R and T402A or C-terminal mutants S490D and Delta 488, is that the former are unable to undergo cell division, whereas the latter continue dividing. These data indicate that localization on the ER results in activation of gamma -PAK, and the increase in association of gamma -PAK with the ER correlates directly with inhibition of cell growth.

Recombinant WT and mutant gamma -PAKs have different expression patterns and different properties in mammalian cells. WT gamma -PAK and S490A migrate as 58-kDa proteins on SDS-PAGE compared with the kinase-inactive mutants K278R and T402A and the active mutant S490D, which migrate as 60-kDa proteins. K278R, T402A, and S490D are expressed at an 8-fold higher level than WT gamma -PAK and S490A. Native gamma -PAK purified from rabbit reticulocytes also has electrophoretically distinct forms; the 58-kDa form is active, whereas the 60-kDa form has little or no protein kinase activity (8). The differences in electrophoretic mobility of the recombinant forms of gamma -PAK during SDS-PAGE correlate with differences in cytostatic activity and could reflect structural differences resulting from mutation or differential phosphorylation of the WT and mutant proteins.

As shown by immunofluorescence, K278R and S490D are expressed at significantly higher levels compared with WT gamma -PAK and S490A and do not localize specifically in the ER. This was confirmed in human embryonic kidney cells by immunofluorescence (data not shown) and by sucrose density gradient analysis. Localization of WT gamma -PAK and S490A, but not kinase-inactive mutants or C-terminal mutants, suggests that both protein kinase activity and localization of gamma -PAK to the ER are required for the induction and maintenance of cytostasis. These conclusions are supported by previous studies showing that gamma -PAK is targeted to the particulate fraction by Cdc42 in response to hyperosmolarity and activated at the membrane (6). Cdc42 also results in growth inhibition in mammalian cells (30, 31). This could occur through activation of gamma -PAK as well as other pathways. The fact that gamma -PAK alone can induce cytostasis indicates that it is a primary effector in inducing and maintaining cell stasis.

A number of substrates have been identified for gamma -PAK (1), suggesting that the molecular mechanisms involved in cytostasis are multifold. Translational initiation factors and ribosomal proteins have been identified as substrates for gamma -PAK2,3 (32, 33), and WT gamma -PAK has been shown to inhibit protein synthesis when transfected into 293T cells, whereas K278R has no effect on translation.2 gamma -PAK in the intermediate density fractions appears to be related to gamma -PAK in the ER. When samples are treated with 1% Nonidet P-40 before centrifugation, gamma -PAK moves from the ER-associated fractions to the intermediate density fraction but not the soluble fraction (data not shown). Thus gamma -PAK associated with the ER and the intermediate density fractions appears to have a common source. Unpublished data3 indicate that gamma -PAK in the intermediate density fractions is bound to ribosomes, suggesting that gamma -PAK on the ER is also bound to ribosomes. Because translation is a major function of the ER, inhibition of translation by gamma -PAK on the ER could lead to inhibition of cell proliferation, although other pathways would also be involved. In this regard, gamma -PAK has been shown to phosphorylate a wide diversity of proteins (1), and the presence of gamma -PAK could also result in phosphorylation of newly synthesized proteins in response to stress.

Because of the cytostatic effects of targeted gamma -PAK, the amount of the protein kinase in the cells is tightly regulated, whereas the levels of nontargeted mutants of gamma -PAK are up to 8-fold higher. The differences in expression levels of the WT enzyme and S490A, and the kinase-inactive mutants and S490D, suggest that mammalian cells can tolerate higher levels of nontargeted gamma -PAK than WT gamma -PAK. It is of interest to note that in addition to regulation of gamma -PAK activity by Cdc42, sphingosine, and caspase cleavage, the level of WT gamma -PAK is tightly regulated by degradation through the proteosome pathway (12). Generally, stress-related proteins, which result in irreversible damage if overexpressed, are tightly regulated in mammalian cells. For instance, WT c-Abl, the tyrosine kinase that has growth-suppressive and apoptotic activities, and the retinoblastoma tumor suppressor protein RB are expressed at significantly lower levels than the corresponding inactive mutant proteins (34, 35). We have shown previously that c-Abl and gamma -PAK are associated in vivo and are cross-phosphorylated (12). In that complex gamma -PAK is protected from degradation and reaches levels approaching those of the kinase-inactive mutants. It is important to note that the cytostatic properties of gamma -PAK are also observed upon expression of gamma -PAK in E. coli.

The majority of endogenous gamma -PAK (85%) is present as soluble enzyme, whereas around 35% of the recombinant WT gamma -PAK and S490D is soluble. These differences can be correlated with the growth status of the cells. The cells containing only endogenous gamma -PAK are dividing; thus the majority of gamma -PAK is present as inactive enzyme. In cells treated by ionizing radiation, >50% of the endogenous gamma -PAK becomes associated with the particulate fractions, concomitant with the inhibition of cell division. Similarly, cells overexpressing WT gamma -PAK and S490A are not dividing, and active gamma -PAK accumulates in the ER. Intracellular localization is also involved in the functioning of other PAK family members, including alpha -PAK. Interaction of alpha -PAK with adaptor proteins such as Nck is implicated in translocation and stimulation of alpha -PAK activity by growth factors (13, 19, 20). Activation of Cdc42 localizes alpha -PAK to areas of membrane ruffling and reformation of the cytoskeleton (13, 36).

Delta 488, a truncated mutant simulating a spontaneous frameshift mutant, provides further evidence that Ser-490 and the C-terminal regulatory region have an important role in subcellular localization and induction of cytostasis. Delta 488 has protein kinase activity similar to that of the WT but is expressed at higher levels than WT gamma -PAK and exists only as a soluble form. The lack of specific localization observed with S490D and Delta 488 suggests that the C terminus is involved in regulating the association of gamma -PAK with the ER and that Ser-490 has a key function in this regulation.

The properties of WT and mutant forms of gamma -PAK are summarized in Table I. gamma -PAK proteins that are localized on the ER, including WT and S490A, are expressed at lower levels in mammalian cells and have cytostatic effects. Mutants of gamma -PAK which are not localized on the ER are of two types, the kinase-inactive mutants K278R and T402A, and the active C-terminal mutants Delta 488 and S490D; these enzymes are expressed at up to 8-fold higher levels than WT gamma -PAK and S490A in mammalian cells and do not inhibit cell proliferation. The summarized results suggest that 1) protein kinase activity alone is not sufficient for the cytostatic effect of gamma -PAK; 2) localization to the ER is important for cytostasis; 3) the C-terminal region of gamma -PAK is involved in localization, as shown with Delta 488, S490A, and S490D, and has a role in mediating the cytostatic effects of gamma -PAK. Ser-490 in the sequence KRGS is a potential recognition and/or phosphorylation site for several protein kinases including gamma -PAK, and phosphorylation at this site, as shown with S490A and S490D, appears to be important in regulating localization of gamma -PAK in the ER. Ser-490 has not been identified as a phosphorylation site in studies examining the autophosphorylation or phosphorylation of gamma -PAK (24); however if Ser-490 is phosphorylated only when gamma -PAK is associated with the ER, it would not have been detected in those studies.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Effects of expression of wild type and mutant gamma -PAK

To evaluate the significance of Ser-490 in gamma -PAK, the tertiary structure of the catalytic domain of gamma -PAK was modeled using the SWISS-MODEL program based on the x-ray crystal structures of alpha -PAK (37). The two predicted subdomains of gamma -PAK form a "catalytic cavity," with Lys-278 located inside (Fig. 7A). Thr-402 in gamma -PAK corresponds to the highly conserved threonine in many protein kinases, which is located in the activation loop (38-40). Thr-402 is an autophosphorylation site and is required for activation of gamma -PAK (9, 23). Ser-490 is located on the opposite side of the catalytic domain, on the surface of an alpha -helix bundle that may serve as an "interface" to interact with other proteins. The beta  subunit of the heterotrimeric G protein has been shown to bind to Ste20, mouse mPAK3, rat alpha -PAK, and yeast Cla4 (26) at a sequence corresponding to residues 505-518 on gamma -PAK, which lies in an alpha -helix near Ser-490. Because of the proximity of Ser-490 to the G protein binding region, it is possible that the trimeric G protein beta  subunit may also participate in the cytostatic response. Thus, Ser-490 may regulate the interaction of gamma -PAK with other components leading to ER localization of gamma -PAK.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Regulatory sites and proposed model for gamma -PAK in cytostasis. A, the tertiary structure of the catalytic domain (amino acids 228-521) of gamma -PAK was predicted using the SWISS MODEL program at www.expasy.ch/swissmod/course/text/submit.htm. The reference protein used for modeling was the catalytic domain of human alpha -PAK (37). B, a model for localization of gamma -PAK on the ER and induction of cytostasis is shown. The C terminus, including Ser-490, regulates the localization of gamma -PAK to the ER as described under "Discussion." Phosphorylation of Ser-490 or removal of the C-terminal region (indicated by the Delta 488 mutant) and/or a lack of autophosphorylation of Thr-402 could prevent gamma -PAK from associating with the ER or enhance dissociation from the ER.

The absence of phosphate on Ser-490 alone (mimicked by S490A) is not sufficient to lead to ER localization of gamma -PAK. As shown in Fig. 5, mutant K278R/S490A is not localized on the ER and has no cytostatic properties (data not shown). This implies that autophosphorylation and activation of gamma -PAK are required for ER localization. A schematic model for regulating the targeting and functioning of gamma -PAK in the induction of cytostasis is shown in Fig. 7B. When Ser-490 is not phosphorylated and Thr-402 is phosphorylated, gamma -PAK would be active and associated with ER, and cells would undergo cytostasis. When Ser-490 is phosphorylated, or when Thr-402 is not phosphorylated, gamma -PAK is not associated with ER, and cells could proliferate normally. Deletion of the C-terminal region containing Ser-490 also prevents ER association and thus would prevent induction of cytostasis.

    ACKNOWLEDGEMENTS

We thank Dr. Xuan Liu for providing anti-HA tag antibody and for helpful discussions, Drs. Gerald Litwack and Emad S. Alnemri for providing the plasmid for expression of caspase 3, Dr. Kevin Orton for preparation of caspase 3, Barbara Walter for technical support, and Dr. Polygena Tuazon and Yuan-Hao Hsu for helpful suggestions.

    FOOTNOTES

* This research was supported by United States Public Health Service Grant GM26738 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: G. W. Hooper Foundation, University of California, 513 Parnassus Ave. HSW1501, San Francisco, CA 94143-0552.

§ To whom correspondence should be addressed. Fax: 909-787-3590; E-mail: jolinda.traugh@ucr.edu.

Published, JBC Papers in Press, January 30, 2003, DOI 10.1074/jbc.M212557200

2 J. Ling, S. J. Morley, and J. A. Traugh, manuscript in preparation.

3 Z. Huang, K. Orton, L. Xu, and J. A. Traugh, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: PAK(s), p21-activated protein kinase; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; ER, endoplasmic reticulum; GTPgamma S, guanosine 5'-O-(thiotriphosphate); HA, hemagglutinin antigen; PBS, phosphate-buffered saline; TRITC, tetramethylrhodamine isothiocyanate; WT, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Roig, J., and Traugh, J. A. (2001) Vitam. Horm. 62, 167-198[Medline] [Order article via Infotrieve]
2. Bagrodia, S., and Cerione, R. A. (1999) Trends Cell Biol. 9, 350-355[CrossRef][Medline] [Order article via Infotrieve]
3. Knaus, U. G., and Bokoch, G. M. (1998) Cell Biol. 30, 857-862
4. Jaffer, Z. M., and Chernoff, J. (2002) Int. J. Biochem. Cell Biol. 34, 713-717[CrossRef][Medline] [Order article via Infotrieve]
5. Manser, E., and Lim, L. (1999) Prog. Mol. Subcell. Biol. 22, 115-133[Medline] [Order article via Infotrieve]
6. Roig, J., Huang, Z., Lytle, C., and Traugh, J. A. (2000) J. Biol. Chem. 275, 16933-16940[Abstract/Free Full Text]
7. Roig, J., and Traugh, J. A. (1999) J. Biol. Chem. 274, 31119-31122[Abstract/Free Full Text]
8. Rooney, R. D., Tuazon, P. T., Meek, W. E., Carroll, E. J., Jr., Hagen, J. J., Gump, E. L., Monnig, C. A., Lugo, T., and Traugh, J. A. (1996) J. Biol. Chem. 271, 21498-21504[Abstract/Free Full Text]
9. Walter, B. N., Huang, Z., Jakobi, R., Tuazon, P. T., Alnemri, E. S., Litwack, G., and Traugh, J. A. (1998) J. Biol. Chem. 273, 28733-28739[Abstract/Free Full Text]
10. Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and Williams, L. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13642-13647[Abstract/Free Full Text]
11. Rudel, T., Zenke, F. T., Chuang, T. H., and Bokoch, G. M. (1998) J. Immunol. 160, 7-11[Abstract/Free Full Text]
12. Roig, J., Tuazon, P. T., Zipfel, P. A., Pendergast, A. M., and Traugh, J. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 14346-14351[Abstract/Free Full Text]
13. Dharmawardhane, S., Sanders, L. C., Martin, S. S., Daniels, R. H., and Bokoch, G. M. (1997) J. Cell Biol. 138, 1265-1278[Abstract/Free Full Text]
14. Galisteo, M. L., Chernoff, J., Su, Y. C., Skolnik, E. Y., and Schlessinger, J. (1996) J. Biol. Chem. 271, 20997-21000[Abstract/Free Full Text]
15. Schmitz, U., Ishida, T., Ishida, M., Surapisitchat, J., Hasham, M. I., Pelech, S., and Berk, B. C. (1998) Circ. Res. 82, 1272-1278[Abstract/Free Full Text]
16. Bokoch, G. M., Reilly, A. M., Daniels, R. H., King, C. C., Olivera, A., Spiegel, S., and Knaus, U. G. (1998) J. Biol. Chem. 273, 8137-8144[Abstract/Free Full Text]
17. Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M., and Chernoff, J. (1997) Curr. Biol. 7, 202-210[Medline] [Order article via Infotrieve]
18. Manser, E., Huang, H.-Y., Loo, T.-H., Chen, X.-Q., Dong, J.-M., Leung, T., and Lim, L. (1997) Mol. Cell. Biol. 17, 1129-1143[Abstract]
19. Bokoch, G. M., Wang, Y., Bohl, B. P., Sells, M. A., Quilliam, L. A., and Knaus, U. G. (1996) J. Biol. Chem. 271, 25746-25749[Abstract/Free Full Text]
20. Lu, W., Katz, S., Gupta, R., and Mayer, B. J. (1997) Curr. Biol. 7, 85-94[Medline] [Order article via Infotrieve]
21. Peter, M., Neiman, A. M., Park, H. O., Van Lohuizen, M., and Herskowitz, I. (1996) EMBO J. 15, 7046-7059[Abstract]
22. Jakobi, R., Huang, Z., Walter, B. N., Tuazon, P. T., and Traugh, J. A. (2000) Eur. J. Biochem. 267, 4456-4464[Abstract/Free Full Text]
23. Tuazon, P. T., Chinwah, M., and Traugh, J. A. (1998) Biochemistry 37, 17024-17029[CrossRef][Medline] [Order article via Infotrieve]
24. Gatti, A., Huang, Z., Tuazon, P. T., and Traugh, J. A. (1999) J. Biol. Chem. 274, 8022-8028[Abstract/Free Full Text]
25. Tuazon, P. T., Spanos, W. C., Gump, E. L., Monnig, C. A., and Traugh, J. A. (1997) Biochemistry 36, 16059-16064[CrossRef][Medline] [Order article via Infotrieve]
26. Leeuw, T., Wu, C., Schrag, J. D., Whiteway, M., Thomas, D. Y., and Leberer, E. (1998) Nature 391, 191-195[CrossRef][Medline] [Order article via Infotrieve]
27. Roig, J., Tuazon, P. T., and Traugh, J. A. (2001) FEBS Lett. 507, 195-199[CrossRef][Medline] [Order article via Infotrieve]
28. Rexach, M. F., and Schekman, R. W. (1991) J. Cell Biol. 114, 219-229[Abstract]
29. Sfeir, C., and Veis, A. (1995) J. Bone Miner. Res. 10, 607-615[Medline] [Order article via Infotrieve]
30. Molnar, A., Theodoras, A. M., Zon, L. I., and Kyriakis, J. M. (1997) J. Biol. Chem. 272, 13229-13235[Abstract/Free Full Text]
31. Dutartre, H., Davoust, J., Gorvel, J. P., and Chavrier, P. (1996) J. Cell Sci. 109, 367-377[Abstract/Free Full Text]
32. Tuazon, P. T., Merrick, W. C., and Traugh, J. A. (1989) J. Biol. Chem. 264, 2773-2777[Abstract/Free Full Text]
33. Del Grande, R. W., and Traugh, J. A. (1982) Eur. J. Biochem. 123, 421-428[Abstract]
34. Goga, A., Liu, X., Hambuch, T. M., Senechal, K., Major, E., Berk, A. J., Witte, O. N., and Sawyers, C. L. (1995) Oncogene 11, 791-799[Medline] [Order article via Infotrieve]
35. Herwig, S., and Strauss, M. (1997) Eur. J. Biochem. 246, 581-601[Abstract]
36. Lu, W., and Mayer, B. J. (1999) Oncogene 18, 797-806[CrossRef][Medline] [Order article via Infotrieve]
37. Lei, M., Lu, W., Meng, W., Parrini, M. C., Eck, M. J., Mayer, B. J., and Harrison, S. C. (2000) Cell 102, 387-397[Medline] [Order article via Infotrieve]
38. Hanks, S. K., and Quinn, A. M. (1991) Methods Enzymol. 200, 38-62[Medline] [Order article via Infotrieve]
39. Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N. P. (1995) Nature 376, 313-320[CrossRef][Medline] [Order article via Infotrieve]
40. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Cell 85, 149-158[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.